DATA: 25 e 26 de Abril de 2024
FORMATO: Híbrido = Presencial ou Online
Apresentação:
• O curso aborda as diferentes facetas do cuidado de pacientes com neoplasias cutâneas a partir dos pilares que sustentam o cuidado centralizado no paciente, incluindo multidisciplinaridade, cooperação
entre equipes e especialização.
Público-alvo:
• Dermatologistas, oncologistas clínicos, rádio oncologistas e cirurgiões oncológicos, além de acadêmicos e profissionais de saúde interessados no diagnóstico e no tratamento dos tumores cutâneos.
Comitê Científico:
• Núcleo de Oncologia Cutânea e Sarcomas do Hospital Sírio Libanês (Group of Cutaneous Malignancies and Sarcomas – Hospital Sírio Libanês)
• Centro de Oncologia do Hospital Sírio Libanês (Oncology Center – Hospital Sírio Libanês)
• Núcleo de Dermatologia do Hospital Sírio Libanês (Dermatology Service – Hospital Sírio Libanês)
| Track | Topic |
|
Melanoma |
Moving forward with melanoma screening – how to identify appropriate subgroups? |
|
Melanoma |
Pathologic response assessment in melanoma – challenges and opportunities |
|
Melanoma |
Surgical aspects in the era of neoadjuvant treatment in melanoma |
|
Melanoma |
Dermatology insights: how not to miss the diagnosis of a melanoma in patients with multiple nevi? |
|
Melanoma |
GEP and molecular prognostic tools in melanoma – current applications |
|
Melanoma |
Are we ready for adaptive strategies according to the path response in patients with melanoma undergoing neoadjuvant treatment? |
|
Melanoma |
Sentinel LN biopsy in mucosal melanoma: controversies and recommendations |
|
Melanoma |
TIL therapy in melanoma – updates and perspectives |
|
Melanoma |
Microscopically controlled surgery in melanoma – current indications |
|
Melanoma |
Interactive case discussions: Spitzoid melanoma |
|
Melanoma |
Interactive case discussions: recurrence following adjuvant treatment in melanoma |
|
Melanoma |
Current adjuvant treatment options for high-risk stage II melanoma and future perspectives |
|
Melanoma |
Approach to stage III melanoma |
|
Melanoma |
Intralesional therapies in melanoma – updates and perspectives |
|
Melanoma |
Overcoming resistance to IT in advanced melanoma |
|
Melanoma |
Optimizing the benefit from ICP: DOs and DON’Ts |
|
Melanoma |
Debate: oligometastatic melanoma – surgery first vs systemic treatment first |
|
Melanoma |
Tackling the microbiome: current recommendations and perspectives |
|
Melanoma |
When is RT indicated in melanoma ? |
|
MTD |
Interactive case discussions: optimal approach to challenging irAEs |
|
MTD |
Interactive case discussions: follow up and management of skin cancers in the SOTR |
|
Skin cancers |
Confocal Microscopy: Indications from in vivo to ex vivo |
|
Skin cancers |
Dermatology workshop - aesthetic procedures during systemic therapies – DOs and DON’Ts (90min duration) |
|
Skin cancers |
Treatment duration in patients with advanced cutaneous malignancies receiving ICP - does one size fit all? |
|
Skin cancers |
Genetic counseling in patients with skin cancers: for whom and how |
|
Skin cancers |
Topical therapies in cutaneous malignancies: indications and contraindications |
|
Skin cancers |
Dermoscopy of Basal Cell and Squamous Cell Carcinomas |
|
Skin cancers |
The current role of dermatologic US in cutaneous malignancies |
|
Skin cancers |
Neoadjuvant approaches in NMSC – do the evidences suffice? |
|
Skin cancers |
Systemic therapies in advanced NMSC – an update |